SLC4A11是一种可向标记,与卵巢癌的治疗反应相关
Xin Li1,2, Jia Yuan1,2, Fanchen Wang1,2
1Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, 1508 Longhang Road, Shanghai, 201508, China.
Journal of ovarian research
|July 30, 2025
概括
溶性载体家族4成员11 (SLC4A11) 在卵巢癌中高度表达,促进瘤生长和不良预后. 准SLC4A11可能为卵巢癌治疗提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 溶性载体家族4成员11 (SLC4A11) 在酸盐稳态,新陈代谢,细胞生长和粘附中发挥作用.
- 在卵巢癌 (OC) 中SLC4A11的特定功能仍然在很大程度上未被探索.
- 这项研究研究了SLC4A11在OC的背景下对抗瘤和生物功能的研究.
研究的目的:
- 阐明SLC4A11在卵巢癌发育和进展中的作用.
- 评估SLC4A11作为潜在的生物标志物和OC治疗点.
主要方法:
- 使用TCGA,GTEx和GEO数据集对人类OC组织和细胞系中SLC4A11表达的分析.
- 在OC细胞和异种移植小鼠中进行功能研究,以评估SLC4A11调制的影响.
- 生物信息分析以与SLC4A11与免疫反应和药物敏感性相关联.
主要成果:
- 在OC组织和细胞中,SLC4A11显著过度表达,与不良的患者预后相关.
- 过度表达SLC4A11增强了OC细胞的增殖,迁移和入侵.
- 在SLC4A11中,SLC4A11 knockdown诱导G0/G1细胞周期停止,细胞亡,并抑制瘤生长.
- SLC4A11表达与免疫细胞透和对某些治疗剂的敏感性有关.
结论:
- 在卵巢癌中,SLC4A11具有致癌作用.
- 高SLC4A11表达与OC患者的预后不佳有关.
- SLC4A11代表了OC治疗的潜在可向生物标志物.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K